Core Viewpoint - The company announced a licensing agreement with Zenas for its core product, Orelabrutinib, in the field of multiple sclerosis and other non-oncological treatments, while retaining rights in oncology [1][2]. Group 1: Licensing Agreement Details - The agreement includes a $100 million upfront payment and potential milestone payments, with a total deal value exceeding $2 billion [1]. - Zenas will also issue 7 million shares of common stock to the company, with additional payments tied to clinical development and commercialization milestones [1]. - The agreement allows Zenas to develop and commercialize Orelabrutinib globally for multiple sclerosis and other non-cancer indications [1][2]. Group 2: Product and Market Insights - Orelabrutinib is currently approved for three indications in hematological cancers in China, with ongoing clinical trials for multiple sclerosis [2]. - The company retains exclusive global rights for Orelabrutinib in oncology, establishing a dual strategy of self-research in oncology and licensing in autoimmune diseases [2]. - The new oral IL-17 AA/AF inhibitor and the brain-penetrant oral TYK2 inhibitor are in preclinical stages, targeting autoimmune diseases like psoriasis and psoriatic arthritis [3]. Group 3: Market Context and Future Prospects - The global market for multiple sclerosis treatments is significant, particularly in Europe and North America, where the disease has a higher prevalence [5]. - The company’s Orelabrutinib shows advantages in kinase selectivity and binding affinity, indicating strong clinical development potential [5]. - The oral IL-17 AA/AF inhibitor addresses the challenge of injection-based therapies, which may improve patient compliance [5]. Group 4: Financial Position - As of June 30, 2025, the company holds approximately 7.68 billion yuan in cash and equivalents, indicating a strong financial position within the biotech sector [6].

Core Viewpoint - Zenas BioSciences has entered into a transformative global licensing agreement worth over $2 billion with InnoCare Pharma, acquiring rights to three autoimmune disease drug candidates, including the previously abandoned BTK inhibitor orelabrutinib, indicating a growing trend of collaboration between multinational pharmaceutical companies and Chinese biotech firms [3][5][6]. Group 1: Financial Details - The agreement includes an initial payment of $100 million in cash, with additional milestone payments expected in the following year. Zenas will also issue up to 7 million shares of common stock to InnoCare, contingent on achieving specific milestones by early 2026 [6]. - InnoCare will receive milestone payments throughout the development, registration, and commercialization phases of the three drugs, with the total value of the agreement potentially exceeding $2 billion. Additionally, InnoCare will earn a tiered royalty rate of "high teens" (approximately 15%-19%) on the annual net sales of these drugs [6]. Group 2: Key Drug Candidates - The core asset of the deal is orelabrutinib, an oral BTK inhibitor capable of penetrating the central nervous system, which is crucial for treating multiple sclerosis (MS). This drug was previously licensed to Biogen, which terminated the agreement in early 2023 [8]. - Orelabrutinib is currently approved in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, and it is in Phase III clinical trials globally for primary progressive MS, with plans for a late-stage global trial to start in Q1 2026 [8]. - In addition to orelabrutinib, Zenas has acquired two other drug candidates: obexelimab, a monoclonal antibody targeting B cells for various autoimmune diseases, and an oral IL-17AA/AF inhibitor, along with a brain-penetrating oral TYK2 inhibitor, both of which are still in early development stages [8][9].

Group 1 - The U.S. Senate failed to pass both the Republican and Democratic short-term funding bills, resulting in the continued government shutdown [8] - President Trump stated that negotiations regarding a ceasefire agreement in Gaza are progressing well and he may visit the Middle East soon [8] - The U.S. federal budget deficit for fiscal year 2025 is projected to be $1.8 trillion, a decrease of $8 billion from the previous year [8] Group 2 - The total box office for the 2025 National Day holiday reached over 1.8 billion yuan by October 8 [6] - The number of signed second-hand residential properties in Shenzhen increased by 32.63% year-on-year from September 6 to October 6 [6] - The China-Europe Railway Express has surpassed 3,000 trips this year, 39 days ahead of last year's pace [7] Group 3 - The price of gold reached a new high of $4,040.42 per ounce, with spot gold rising by 1.41% [3][4] - The main contract for U.S. crude oil rose by 0.92% to $62.30 per barrel, while Brent crude increased by 0.9% to $66.04 per barrel [4] - Major U.S. stock indices showed mixed results, with the Nasdaq rising by 1.12% and the S&P 500 increasing by 0.58% [3]

Group 1: US Market Performance - The three major US stock indices closed mixed, with the Nasdaq rising by 1.12% and the S&P 500 increasing by 0.58%, both reaching new closing highs, while the Dow Jones remained nearly flat [4] - Notable tech stocks saw significant gains, with AMD rising over 11% and achieving a three-day cumulative increase of 43%, marking its best three-day performance in nine years [4] - The Nasdaq China Golden Dragon Index rose by 0.87%, with most Chinese concept stocks also experiencing gains, including NIO up over 4% and New Oriental up over 3% [4] Group 2: Federal Reserve Insights - The Federal Reserve's meeting minutes indicated that most officials believe further easing of policies may be appropriate this year, with an emphasis on the upward risks to inflation expectations [4] - Officials noted that recent inflation levels remain high but are expected to gradually return to target levels [4] Group 3: Commodity Prices - Spot gold prices increased by 1.41%, reaching $4040.42 per ounce, with an intraday high of $4059.31, marking a new historical peak [4] - WTI crude oil prices rose by 0.92%, closing at $62.30 per barrel, while Brent crude oil increased by 0.9% to $66.04 per barrel [4] Group 4: European Market Performance - All three major European stock indices closed higher, with Germany's DAX up by 0.87%, France's CAC40 rising by 1.07%, and the UK's FTSE 100 increasing by 0.69% [5] Group 5: Chinese Real Estate Market - In Shenzhen, the number of second-hand residential transactions from September 6 to October 6 increased by 32.63% year-on-year, indicating a significant recovery in the real estate market following new policies [6] Group 6: Automotive Industry Performance - BYD reported a 5.52% year-on-year decline in September sales of new energy vehicles, totaling 396,300 units [11] - SAIC Motor's sales reached approximately 440,000 vehicles in September, marking a 40.4% year-on-year increase, with new energy vehicle sales nearing 190,000 units, up 46.5% [12] Group 7: Mining Sector Developments - Sichuan Gold announced it successfully acquired exploration rights for a gold mine in Xinjiang, which is located in a significant mineral-rich area, potentially enhancing the company's future performance [13][14] Group 8: Corporate Developments - Nobility Healthcare's subsidiary signed a licensing agreement with Zenas BioPharma, involving a total transaction value exceeding $2 billion, which is expected to expand the company's market share and business scope [18][19] - Hainan Huatie's major shareholder decided to terminate a share reduction plan and instead plans to increase holdings in the company by investing between 30 million to 50 million yuan [16] Group 9: International News Impact - The US Senate failed to pass two bipartisan funding bills, resulting in the continued shutdown of the federal government [8] - The US federal budget deficit for the fiscal year 2025 is projected to be $1.8 trillion, a decrease of $80 billion from the previous year [8]

潜在交易额超20亿美元 诺诚健华达成重磅对外授权协议 ◎记者 张雪 奥布替尼被寄予厚望 潜在总交易金额超20亿美元 诺诚健华将获得1亿美元的首付款及近期里程碑付款，以及Zenas发行的700万股普通股。未来，诺诚健 华还有权获得潜在的研发及注册里程碑付款、商业化里程碑付款，并从授权产品的年度净销售额中收取 最高达百分之十几的特许权使用费，总交易金额或将超过20亿美元。 奥布替尼是全球首个进入Ⅲ期临床的中枢神经系统强渗透性BTK抑制剂，针对原发进展型多发性硬化症 （PPMS）的全球Ⅲ期试验已于2025年三季度启动，预计2026年一季度启动继发进展型（SPMS）试 验。此前Ⅱ期数据显示，其显著减少脑部炎症病灶，且安全性优异。 通过此次合作，Zenas将获得奥布替尼在多发性硬化领域的全球独家开发、生产和商业化权利，以及奥 布替尼在非肿瘤领域除大中华区及东南亚地区以外区域的权利。Zenas还将获得口服IL-17AA/AF抑制剂 除大中华区及东南亚地区外的独家开发、生产和商业化权利，以及透脑性口服TYK2抑制剂的全球权 利。"我们预计2026年将这两款抑制剂推向临床，并预计2027年获得口服IL-17AA/AF抑制剂的 ...

Core Insights - The collaboration between Nocera Biopharma and Zenas BioPharma involves a global licensing agreement worth over $2 billion, focusing on the development of Orelabrutinib for multiple sclerosis and other autoimmune diseases [2][4]. Group 1: Agreement Details - Zenas will receive global exclusive rights for Orelabrutinib in the multiple sclerosis field and rights for non-oncology development and commercialization outside Greater China and Southeast Asia [4][5]. - Nocera Biopharma will receive an upfront payment of $100 million, milestone payments, and 7 million shares of common stock from Zenas, along with royalties of up to a percentage of annual net sales from licensed products [4][6]. Group 2: Product Potential - Orelabrutinib is the first highly permeable BTK inhibitor for the central nervous system to enter Phase III clinical trials, with trials for primary progressive multiple sclerosis (PPMS) starting in Q3 2025 and secondary progressive multiple sclerosis (SPMS) trials expected to begin in Q1 2026 [4][8]. - The drug has shown significant efficacy in reducing brain inflammation and has an excellent safety profile based on Phase II data [4][8]. Group 3: Strategic Focus - Nocera Biopharma retains global rights for Orelabrutinib in oncology and non-oncology rights in Greater China and Southeast Asia, indicating a strategic focus on dual therapeutic areas [6][8]. - The company aims to enhance its drug discovery platform to develop first-in-class and best-in-class therapies for autoimmune diseases, addressing unmet medical needs in China and globally [9].

Core Insights - InnoCare Pharma Inc., a wholly-owned subsidiary of the company, has signed a licensing agreement with Zenas BioPharma, granting Zenas global development and commercialization rights for Orelabrutinib in multiple sclerosis and other non-oncology therapeutic areas [1] - Zenas will pay up to $100 million in upfront and milestone payments, with total transaction value exceeding $2 billion, including stock issuance and royalties [1] Group 1 - The agreement includes rights to two preclinical molecules: a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor [1] - Zenas will issue 7 million shares of common stock to the company, with additional payments tied to clinical development, registration, and commercialization milestones [1] - The company is entitled to receive tiered royalties of up to the high teens percentage on annual net sales of the licensed products [1]

Core Insights - The article highlights significant fluctuations in the market prices of silver and tin, which have impacted the stock price of Xingye Silver Tin [1] Performance - Chipone Technology expects a record high quarterly revenue of 1.284 billion yuan for Q3 [1] - Great Wall Motors reported a year-on-year sales increase of 23.29% in September [1] - Foton Motor's total vehicle sales in September grew by 6.08% year-on-year, with new energy vehicle sales increasing by 47.77% [1] - BYD experienced a year-on-year decline of 5.52% in new energy vehicle sales in September [1] - Seres saw a year-on-year sales increase of 8.33% in September [1] - BAIC Blue Valley's subsidiary reported a year-on-year sales increase of 30.15% in September [1] - Yonghe Holdings anticipates a year-on-year net profit increase of 211.59% to 225.25% for the first three quarters [1] Shareholding Changes - Huaxing Yuanchuang's shareholders plan to reduce their holdings by no more than 0.9% [1] - Ruile New Materials' shareholders intend to reduce their holdings by no more than 100,800 shares [1] Share Buybacks - Huaxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [1] Contract Awards - Bomei Technology signed a contract for an offshore floating production storage and offloading vessel project, valued at approximately 190 to 240 million USD [1] - Sichuan Gold acquired exploration rights for the Kugezi-Juebei gold mine in Xinjiang [1] - Weisheng Information won projects totaling 287 million yuan, accounting for 10.45% of the company's expected revenue for 2024 [1] - Innovent Biologics' subsidiary signed a licensing agreement for the drug Orelabrutinib and two preclinical assets, with a total transaction value exceeding 2 billion USD [1] - Runjian Co. plans to bid for a land-based wind power project worth 1.753 billion yuan [1] - Xinjiang Jiaojian intends to bid for a highway construction project valued at 483 million yuan [1] Equity Changes - Delixi Holdings is planning a change in company control, leading to a stock suspension [1] - Bofei Electric plans to transfer 100% equity of its wholly-owned subsidiary Bofei New Energy [1] Other Developments - Dianguang Media holds 4.1288 million shares of Ruili Technology through Dacheng Venture Capital, representing 2.2915% of its post-issue total share capital [1] - Huaxin Cement has terminated plans for a spin-off listing of its overseas subsidiary [1] - Baili Tianheng received approval for clinical trials of BL-ARC001 for late-stage solid tumor treatment [1] - *ST Gaohong received a notice of termination of listing [1] - *ST Jianyi plans to sign an agreement to terminate the investment cooperation for the monocrystalline silicon project and deregister Jianyi Zhengyao [1]

Major Events - Delixi Co., Ltd. is planning a change in control, with stock suspension starting from October 9, 2025, for up to two trading days [1] - Sichuan Gold has won the exploration rights for the Kugez—Juebei gold mine in Xinjiang for 510 million yuan, indicating significant mining potential in a key mineral belt [1] - *ST Gaohong received a notice of termination of listing due to stock prices being below 1 yuan for 20 consecutive trading days [2] - Baili Tianheng's innovative drug BL-ARC001 has received clinical trial approval for treating advanced solid tumors, marking a significant advancement in targeted therapy [3] - Xingye Silver Tin's stock price fluctuation is attributed to significant recent price changes in its main products, silver and tin [3] Performance Overview - BAIC Blue Valley's subsidiary reported a 30.15% year-on-year increase in September sales, totaling 20,539 vehicles [4] - Seres achieved a 19.44% year-on-year increase in September sales, reaching 44,700 new energy vehicles [4] - BYD's September sales of new energy vehicles decreased by 5.52% year-on-year, totaling 396,300 vehicles, with exports of 71,256 vehicles [5] - Chipone Technology expects Q3 revenue of 1.284 billion yuan, a 119.74% increase from the previous quarter and a 78.77% increase year-on-year [5] - Yonghe Holdings anticipates a net profit increase of 448% to 507% for Q3, with projected profits of 456 million to 476 million yuan for the first three quarters [5] Major Contracts - Xinjiang Jiaojian has been awarded a 483 million yuan highway construction project [6] - Longquan Co. is a candidate for a project worth 50.76 million yuan, expected to positively impact revenue and profit [7] - Runjian Co. has secured a design and construction contract for a land-based wind power project valued at 1.753 billion yuan [8] - Innovent Biologics has signed a licensing agreement with Zenas BioPharma for the drug Obrutinib and two preclinical assets, with a total deal value exceeding 2 billion USD [8] Shareholding Changes - Huaxing Yuanchuang announced plans for its employee shareholding platforms to reduce their holdings by up to 0.9% of the company's total shares [9][10]

协议主要条款 对公司影响与风险 本次协议签署将加快奥布替尼及其他管线产品全球开发和商业化进程，是国际化战略重要里程碑，预计 对未来业绩产生积极影响，不影响业务独立性，不会形成依赖。但新药研发风险高、周期长，本次交易 付款需满足条件，最终金额存在不确定性，投资者需谨慎决策。 来源：新浪财经-鹰眼工作室 market诺诚健华10月9日发布公告称，其全资子公司InnoCare Pharma Inc.与Zenas BioPharma, Inc.签署授 权许可协议，将奥布替尼及2项临床前资产有偿许可给Zenas，使其可开发、生产、商业化或以其他方式 利用该等产品。 交易详情 交易审议与双方情况 2025年10月7日，诺诚健华董事会审议通过本次交易，无需提交股东大会审议。主要许可产品：奥布替 尼是处于后期临床阶段、具潜在同类最佳优势的高中枢神经系统渗透性、选择性、不可逆口服小分子 BTK抑制剂。在多发性硬化症领域已启动相关III期临床试验；在自身免疫疾病领域，免疫性血小板减少 症三期注册临床完成患者入组，系统性红斑狼疮IIb期临床数据预计于2025年第四季度公布；在血液肿 瘤领域，自中国上市以来已取得显著临床认可及市场覆 ...